Every 10-Q that BioLife Solutions Inc. (BLFS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BLFS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLFS filings page.
BioLife Solutions, Inc. reported solid growth for the quarter ended June 30, 2026. Revenue was $28.5 million versus $23.4 million a year earlier, generating gross profit of $18.3 million. Operating income was $1.7 million, compared with an operating loss in the prior-year period that included a large IPR&D expense.
Net income from continuing operations was $45.1 million for the quarter, driven largely by a $42.3 million income tax benefit from releasing part of the valuation allowance on deferred tax assets. This lifted shareholders’ equity to $420.0 million and reduced the accumulated deficit.
Liquidity remained strong, with $113.1 million in cash, cash equivalents and available-for-sale securities and the company’s $5.0 million term loan fully repaid by June 1, 2026. SAVSU’s cold-chain business is classified as discontinued operations after its 2025 sale, which generated a $10.3 million gain. Subsequent to quarter-end, BioLife agreed to a cash-and-stock merger with Repligen, under which each share will receive $11.25 in cash and 0.1442 Repligen shares, with closing expected in the fourth quarter of 2026.
BioLife Solutions reported stronger results for the quarter ended March 31, 2026, as revenue rose to $27.5 million, up $5.4 million or 25% from a year earlier. Growth was driven mainly by higher demand for its CryoStor biopreservation media.
Gross profit increased to $17.5 million, though gross margin slipped to 64% from 67% due to a less favorable product mix and more lower-margin products. Operating expenses rose 14% to $17.5 million, led by higher personnel costs and research and development tied to the PanTHERA acquisition.
The company moved from a net loss of $0.4 million to net income of $1.2 million from continuing operations, or $0.02 per diluted share. BioLife ended the quarter with $111.5 million in cash, cash equivalents, and available-for-sale securities and believes this is sufficient to fund operations for at least the next twelve months.
BioLife Solutions (BLFS) reported Q3 results with total revenue of $28.1 million, up from $21.4 million a year ago, and net income of $0.6 million ($0.01 per share). Operating loss narrowed to $0.09 million, aided by $0.8 million in other income. For the first nine months, revenue was $77.4 million and net loss was $15.7 million, reflecting a $15.5 million IPR&D expense tied to the PanTHERA acquisition.
Cash, cash equivalents, and available-for-sale securities totaled $98.4 million at September 30, 2025. Year-to-date, operating cash flow was $15.2 million, investing used $72.7 million (including marketable securities purchases and IPR&D), and financing used $8.4 million as the company repaid $7.5 million on term loans. Shareholders’ equity was $353.7 million.
Management continues to focus on higher-margin bioproduction products after divesting several businesses in 2024. The company completed the PanTHERA transaction (accounted for as an asset acquisition) and, subsequent to quarter-end, signed an agreement to sell SAVSU, which remains in continuing operations for this period.